Erythroderma as the first paraneoplastic manifestation of early-stage lung squamous cell carcinoma: a rare case report
DOI:
https://doi.org/10.18203/2320-6012.ijrms20261354Keywords:
Erythroderma, Lung squamous cell carcinoma, Early-stage lung cancer, Cutaneous paraneoplastic manifestation, Systemic malignancy with skin involvementAbstract
Erythroderma is a severe inflammatory dermatosis affecting over 90% of the body surface area and commonly arises from pre-existing dermatoses or drug reactions. Paraneoplastic erythroderma is rare but clinically significant, especially in elderly patients, as it may precede the diagnosis of internal malignancy. Early identification and evaluation are essential for timely detection. An 85-year-old male with a 40 pack-year smoking history presented with rapidly progressive generalized erythema and scaling, without prior dermatologic disease or new medication exposure. Skin biopsy revealed subacute spongiotic dermatitis with dermal eosinophils. Given the unexplained presentation and patient’s risk factors, systemic evaluation was pursued. Imaging demonstrated a right lower-lobe perihilar mass, and bronchoscopy with biopsy confirmed moderately differentiated squamous cell carcinoma of the lung. Supportive dermatologic therapy was initiated and sequential chemo-radiation was planned. Improvement in the erythroderma paralleled initiation of cancer-directed therapy. Erythroderma can rarely be the first manifestation of lung squamous cell carcinoma. In elderly patients with unexplained erythroderma, especially those with smoking history, malignancy screening should be undertaken after exclusion of common causes.
References
Akhyani M, Ghodsi SZ, Toosi S, Dabbaghian H. Erythroderma: A clinical study of 97 cases. BMC Dermatol. 2005;5:5.
Sigurdsson V, Toonstra J, Withagen C, van Vloten WA. Erythroderma: A clinical and follow-up study of 102 patients, with special emphasis on survival. J Am Academy Dermatol. 1996;35(1):53-7.
Plachouri KM, Georgiou S. Paraneoplastic erythroderma: An insight into the existing data. Int J Dermatol. 2020;59(12):1429-36.
Arandes-Marcocci J, Iglesias-Sancho M, Setó-Torrent N, Simal-Aldea EM, María TFF. Erythroderma as the first manifestation of lung squamous cell carcinoma: a rare case report. Anais Brasileiros de Dermatologia. 2019;94(1):67-71.
Zervakis SG, Spernovasilis N, Boutakoglou E, Simeon P, Konstantina T, George S. Erythroderma as a paraneoplastic manifestation of small-cell lung cancer: Case report and review of the literature. Curr Problems Cancer. 2020;44(2):100499.
Erden N, Khoshbakht S, Yaycioglu A, Kizilirmak AB, Kayalar O, Demirkesen C, et al. Lung adenocarcinoma presenting with eosinophilic erythroderma associated with anti-KRT6B antibodies: A paraneoplastic case report. J Europ Academy Dermatol Venereol. 2023;37(12):e895-7.
Kahana M, Kurban AK. Cutaneous paraneoplastic syndromes associated with lung carcinoma. Am J Clin Dermatol. 2004;5(2):75-83.
Kanitakis J. Paraneoplastic cutaneous manifestations: A review. Clin Dermatol. 2011;29(6):627-38.
Fonseca G, Ahmed H, Graham L, Elston DM. Paraneoplastic erythroderma: Clinicopathological features and patterns of dermatitis. J Cutan Pathol. 2021;48(6):800-7.
Kliniec K, Snopkowska A, Łyko M, Jankowska-Konsur A. Erythroderma-A retrospective analysis of clinical characteristics and outcomes in adult patients. J Clin Med. 2024;13(3):645.
Boyd AS, Neldner KH. Exfoliative dermatitis. Dermatol Clin. 1994;12(2):309-22.
Sehgal VN, Srivastava G. Erythroderma/exfoliative dermatitis: A prospective study of etiological and prognostic factors in adults. Int J Dermatol. 2006;45(10):1179-82.
Bolognia JL, Schaffer JV, Cerroni L. Dermatology. 4th ed. Elsevier. 2018.